Buy, Sell, Or Hold GILD Stock?
23/6 06:05
Despite a recent setback involving an FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to declines in CD4+ T-cell counts, Gilead Sciences (NASDAQ:GILD) has posted a strong year-to-date performance, with its stock rising 18% compared to the S&P 500’s mod...